Literature DB >> 10379855

Transcatheter embolization for the treatment of misperfusion after hepatic artery chemoinfusion pump implantation.

A I Bloom1, R L Gordon, K H Ahl, R K Kerlan, J M LaBerge, M W Wilson, A P Venook, R Warren.   

Abstract

BACKGROUND: The use of surgically implanted chemoinfusion pumps for the treatment of hepatic metastases from colorectal carcinoma can be complicated by intra- or extrahepatic misperfusion. This may result in suboptimal tumor exposure to the chemotherapeutic agent and injury to other gastrointestinal organs. Misperfusion can be managed by selective arterial transcatheter embolization.
METHODS: Between 1989 and 1996, 16 patients with liver metastases from colorectal carcinoma and with hepatic artery chemoinfusion pump misperfusion were treated using transcatheter coil embolization. Six female and 10 male patients (age range, 34-84 years; median, 51.5 years) were identified by retrospective review of the records of the Department of Interventional Radiology. After pump placement, abnormal liver perfusion scan or methylene blue endoscopy study results prompted angiography with coil embolization. After embolization, the imaging studies were repeated and patients were monitored in the Oncology Clinic.
RESULTS: Eight patients exhibited intrahepatic misperfusion (group 1) and eight extrahepatic misperfusion (group 2). Coil embolization was immediately successful in 100% of patients in group 1, with restoration of normal hepatic perfusion, and in 75% in group 2. There were no immediate procedure-related complications. Follow-up periods ranged from 1 to 23 months (median, 13.5 months). Embolization was unsuccessful for two patients (in group 2), who tolerated a modified chemotherapeutic regimen, with follow-up periods of 18.5 and 22 months.
CONCLUSIONS: Transcatheter coil embolization is the therapy of choice for the management of hepatic artery chemoinfusion pump misperfusion. It is rapid, effective, and well tolerated by patients and obviates the need for additional surgical intervention.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10379855     DOI: 10.1007/s10434-999-0350-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  4 in total

1.  Hepatic artery chemotherapy in the management of colorectal metastases.

Authors:  Stacy L Stratmann
Journal:  Proc (Bayl Univ Med Cent)       Date:  2002-10

2.  Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement.

Authors:  P J Karanicolas; P Metrakos; K Chan; T Asmis; E Chen; T P Kingham; N Kemeny; G Porter; R C Fields; J Pingpank; E Dixon; A Wei; S Cleary; G Zogopoulos; C Dey; M D'Angelica; Y Fong; S Dowden; Y J Ko
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

Review 3.  Current treatment for liver metastases from colorectal cancer.

Authors:  Lian-Xin Liu; Wei-Hui Zhang; Hong-Chi Jiang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

4.  Interventional management of gastroduodenal lesions complicating intra-arterial hepatic chemotherapy.

Authors:  Stefania Proietti; Thierry De Baere; Bertrand Bessoud; Francesco Doenz; Salah Dine Qanadli; Pierre Schnyder; Alban Denys
Journal:  Eur Radiol       Date:  2007-01-12       Impact factor: 7.034

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.